Windlas Biotech [WINDLAS] vs Sun Pharma Advanced [SPARC] Detailed Stock Comparison

Windlas Biotech Ltd.

NSE
Loading...

Sun Pharma Advanced Research Company Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Windlas Biotech Ltd. wins in 14 metrics, Sun Pharma Advanced Research Company Ltd. wins in 4 metrics, with 0 ties. Windlas Biotech Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Windlas Biotech Ltd. Sun Pharma Advanced Research Company Ltd. Better
P/E Ratio (TTM) 27.93 -13.65 Windlas Biotech Ltd.
Price-to-Book Ratio 3.45 -13.55 Windlas Biotech Ltd.
Debt-to-Equity Ratio 5.84 -1.21 Windlas Biotech Ltd.
PEG Ratio -6.31 -11.15 Windlas Biotech Ltd.
EV/EBITDA 14.83 -22.27 Windlas Biotech Ltd.
Profit Margin (TTM) 7.69% -53.22% Windlas Biotech Ltd.
Operating Margin (TTM) 7.16% -700.71% Windlas Biotech Ltd.
EBITDA Margin (TTM) 7.16% N/A N/A
Return on Equity 12.06% 157.88% Sun Pharma Advanced Research Company Ltd.
Return on Assets (TTM) 8.02% -102.08% Windlas Biotech Ltd.
Free Cash Flow (TTM) $159.93M $-3.71B Windlas Biotech Ltd.
Dividend Yield 1.23% N/A N/A
1-Year Return -11.61% 34.88% Sun Pharma Advanced Research Company Ltd.
Price-to-Sales Ratio (TTM) 2.14 87.98 Windlas Biotech Ltd.
Enterprise Value $16.09B $50.87B Sun Pharma Advanced Research Company Ltd.
EV/Revenue Ratio 1.85 95.73 Windlas Biotech Ltd.
Gross Profit Margin (TTM) 38.44% -59.53% Windlas Biotech Ltd.
Revenue per Share (TTM) $414 $2 Windlas Biotech Ltd.
Earnings per Share (Diluted) $31.45 $-8.25 Windlas Biotech Ltd.
Beta (Stock Volatility) 0.22 0.19 Sun Pharma Advanced Research Company Ltd.

Windlas Biotech Ltd. vs Sun Pharma Advanced Research Company Ltd. Stock Performance Analysis

Loading Price Chart...

WINDLAS
SPARC

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Windlas Biotech Ltd.-0.62%0.61%5.11%16.08%4.89%2.18%
Sun Pharma Advanced Research Company Ltd.2.36%12.49%39.95%100.62%67.89%69.61%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Windlas Biotech Ltd.-11.61%173.72%124.79%124.79%124.79%124.79%
Sun Pharma Advanced Research Company Ltd.34.88%14.54%-3.55%-20.47%148.26%-23.02%

Performance & Financial Health Analysis: Windlas Biotech Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricWINDLASSPARC
Market Information
Market Cap i₹18.15B₹46.75B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i59,2532,401,062
90 Day Avg. Volume i45,1782,083,443
Last Close₹819.20₹229.03
52 Week Range₹697.40 - ₹1,097.90₹108.00 - ₹248.75
% from 52W High-25.38%-7.93%
All-Time High₹1,198.25 (Nov 04, 2024)₹875.00 (Apr 24, 2006)
% from All-Time High-31.63%-73.83%
Growth Metrics
Quarterly Revenue Growth0.20%-0.43%
Quarterly Earnings Growth-0.04%-0.43%
Financial Health
Profit Margin (TTM) i0.08%-0.53%
Operating Margin (TTM) i0.07%-7.01%
Return on Equity (TTM) i0.12%1.58%
Debt to Equity (MRQ) i5.84-1.21
Cash & Liquidity
Book Value per Share (MRQ)₹254.44₹-10.63
Cash per Share (MRQ)₹125.24₹0.03
Operating Cash Flow (TTM) i₹396.84M₹-3,484,287,000
Levered Free Cash Flow (TTM) i₹609.94M₹-3,425,094,000
Dividends
Last 12-Month Dividend Yield i1.23%N/A
Last 12-Month Dividend i₹11.30N/A

Valuation & Enterprise Metrics Analysis: Windlas Biotech Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricWINDLAS (Apr 24, 2026)SPARC (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i27.93-13.65
Forward P/E iN/A2.60
PEG Ratio i-6.31-11.15
Price to Sales (TTM) i2.1487.98
Price to Book (MRQ) i3.45-13.55
Market Capitalization
Market Capitalization i₹18.15B₹46.75B
Enterprise Value i₹16.09B₹50.87B
Enterprise Value Metrics
Enterprise to Revenue i1.8595.73
Enterprise to EBITDA i14.83-22.27
Risk & Other Metrics
Beta i0.220.19
Book Value per Share (MRQ) i₹254.44₹-10.63

Financial Statements Comparison: Windlas Biotech Ltd. vs Sun Pharma Advanced Research Company Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricWINDLAS (2025)SPARC (2025)
Revenue/Sales i7.55B717.66M
Cost of Goods Sold i4.72B1.10B
COGS % of Revenue i62.5%153.2%
Gross Profit i2.83B-381.94M
Gross Margin i37.5%-53.2%
Research & Development i62.51MN/A
Operating Income (EBIT) i666.10M-3.34B
Operating Margin i8.8%-465.5%
EBITDA i971.54M-3.23B
EBITDA Margin i12.9%-450.0%
Pre-Tax Income i797.58M-3.43B
Pre-Tax Income % of Revenue i10.6%-477.6%
Income Tax i187.64M-2.72M
Income Tax % of Revenue i2.5%-0.4%
Net Income (Profit) i609.94M-3.43B
Profit Margin i8.1%-477.3%

Balance Sheet & Liquidity Metrics

MetricWINDLAS (2025)SPARC (2025)
Cash & Equivalents i4.24M19.64M
Total Current Assets i5.25B261.97M
Total Current Assets % of Revenue i69.5%36.5%
Total Current Liabilities i2.49B3.74B
Total Current Liabilities % of Revenue i33.0%521.5%
Long-Term Debt i22.51M1.07B
Long-Term Debt % of Revenue i0.3%149.0%
Total Shareholders Equity i5.06B-2.17B
Retained Earnings i2.75B-23.22B
Retained Earnings % of Revenue i36.4%-3,235.0%
Property, Plant & Equipment i65.84M178.02M

Cash Flow Statement Comparison

MetricWINDLAS (2025)SPARC (2025)
Operating Cash Flow i396.84M-3.48B
Operating Cash Flow % of Revenue i5.3%-485.5%
Capital Expenditures i-519.97M-97.45M
Free Cash Flow i159.93M-3.71B
FCF Margin i2.1%-516.4%
Debt Repayment i0-3.69B
Common Stock Repurchase i0N/A

Short Interest & Institutional Ownership Analysis

MetricWINDLASSPARC
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i21.11M324.52M
Float Shares i7.62M91.32M
% Held by Insiders i65.75%72.96%
% Held by Institutions i8.46%2.56%
% Held by Public i25.79%24.48%

Dividend Analysis & Yield Comparison: Windlas Biotech Ltd. vs Sun Pharma Advanced Research Company Ltd.

MetricWINDLASSPARC
Last 12-Month Dividend i₹11.30N/A
Last 12-Month Dividend Yield i1.23%N/A
3-Year Avg Annual Dividend i₹6.27N/A
3-Year Avg Dividend Yield i0.96%N/A
3-Year Total Dividends i₹18.80N/A
Ex-Dividend DateJul 21, 2025N/A